Can Persistence With Cholinesterase Inhibitor Treatment Lower Mortality and Health-Care Costs Among Patients With Alzheimer’s Disease? A Population-Based Study in Taiwan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Although cholinesterase inhibitors (ChEIs) have been proved to help reduce cognitive deterioration in patients with Alzheimer’s disease (AD), their effects on survival remain inconclusive. This study aims to assess the effects of the persistent use of ChEIs on the risk of mortality in patients with AD. This population-based cohort study included 8614 patients having AD with ChEI prescription from 2002 to 2006 and followed until 2010. Kaplan-Meier curves and hazard ratios (HRs) of mortality were estimated in association with ChEI treatment duration and adherence. The average annual mortality rate per 100 person-years was 9.2 for the short-duration group (discontinued < 1 year) and 7.2 for the long-duration group (discontinued ≥ 2 years). Compared to the short-duration group, the long-duration group had a lower mortality (HR = 0.76, 95% confidence interval: 0.69-0.84) and shorter annual inpatient days. But the annual health-care costs did not differ significantly between the 2 groups.

Original languageEnglish
Pages (from-to)86-92
Number of pages7
JournalAmerican Journal of Alzheimer's Disease and other Dementias
Volume33
Issue number2
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

Cholinesterase Inhibitors
Taiwan
Health Care Costs
Alzheimer Disease
Mortality
Population
Therapeutics
Prescriptions
Inpatients
Cohort Studies
Confidence Intervals
Survival

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

@article{74e99a8e637343dcbeafe7410a27e05c,
title = "Can Persistence With Cholinesterase Inhibitor Treatment Lower Mortality and Health-Care Costs Among Patients With Alzheimer’s Disease? A Population-Based Study in Taiwan",
abstract = "Although cholinesterase inhibitors (ChEIs) have been proved to help reduce cognitive deterioration in patients with Alzheimer’s disease (AD), their effects on survival remain inconclusive. This study aims to assess the effects of the persistent use of ChEIs on the risk of mortality in patients with AD. This population-based cohort study included 8614 patients having AD with ChEI prescription from 2002 to 2006 and followed until 2010. Kaplan-Meier curves and hazard ratios (HRs) of mortality were estimated in association with ChEI treatment duration and adherence. The average annual mortality rate per 100 person-years was 9.2 for the short-duration group (discontinued < 1 year) and 7.2 for the long-duration group (discontinued ≥ 2 years). Compared to the short-duration group, the long-duration group had a lower mortality (HR = 0.76, 95{\%} confidence interval: 0.69-0.84) and shorter annual inpatient days. But the annual health-care costs did not differ significantly between the 2 groups.",
author = "Ku, {Li-Jung Elizabeth} and Chung-Yi Li and Yu Sun",
year = "2018",
month = "3",
day = "1",
doi = "10.1177/1533317517734639",
language = "English",
volume = "33",
pages = "86--92",
journal = "American Journal of Alzheimer's Disease and other Dementias",
issn = "1533-3175",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Can Persistence With Cholinesterase Inhibitor Treatment Lower Mortality and Health-Care Costs Among Patients With Alzheimer’s Disease? A Population-Based Study in Taiwan

AU - Ku, Li-Jung Elizabeth

AU - Li, Chung-Yi

AU - Sun, Yu

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Although cholinesterase inhibitors (ChEIs) have been proved to help reduce cognitive deterioration in patients with Alzheimer’s disease (AD), their effects on survival remain inconclusive. This study aims to assess the effects of the persistent use of ChEIs on the risk of mortality in patients with AD. This population-based cohort study included 8614 patients having AD with ChEI prescription from 2002 to 2006 and followed until 2010. Kaplan-Meier curves and hazard ratios (HRs) of mortality were estimated in association with ChEI treatment duration and adherence. The average annual mortality rate per 100 person-years was 9.2 for the short-duration group (discontinued < 1 year) and 7.2 for the long-duration group (discontinued ≥ 2 years). Compared to the short-duration group, the long-duration group had a lower mortality (HR = 0.76, 95% confidence interval: 0.69-0.84) and shorter annual inpatient days. But the annual health-care costs did not differ significantly between the 2 groups.

AB - Although cholinesterase inhibitors (ChEIs) have been proved to help reduce cognitive deterioration in patients with Alzheimer’s disease (AD), their effects on survival remain inconclusive. This study aims to assess the effects of the persistent use of ChEIs on the risk of mortality in patients with AD. This population-based cohort study included 8614 patients having AD with ChEI prescription from 2002 to 2006 and followed until 2010. Kaplan-Meier curves and hazard ratios (HRs) of mortality were estimated in association with ChEI treatment duration and adherence. The average annual mortality rate per 100 person-years was 9.2 for the short-duration group (discontinued < 1 year) and 7.2 for the long-duration group (discontinued ≥ 2 years). Compared to the short-duration group, the long-duration group had a lower mortality (HR = 0.76, 95% confidence interval: 0.69-0.84) and shorter annual inpatient days. But the annual health-care costs did not differ significantly between the 2 groups.

UR - http://www.scopus.com/inward/record.url?scp=85040934431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040934431&partnerID=8YFLogxK

U2 - 10.1177/1533317517734639

DO - 10.1177/1533317517734639

M3 - Article

C2 - 29210284

AN - SCOPUS:85040934431

VL - 33

SP - 86

EP - 92

JO - American Journal of Alzheimer's Disease and other Dementias

JF - American Journal of Alzheimer's Disease and other Dementias

SN - 1533-3175

IS - 2

ER -